Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.88 |
| ▸ | MAPT | P10636 | 4/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040109 | 0.79 | KMT2A (0.56) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL7989609 | 0.77 | MEN1 (0.56) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8000480 | 0.77 | MAPT (0.56) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8051518 | 0.77 | KMT2A (0.53) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL10658820 | 0.75 | MEN1 (0.54) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8052438 | 0.74 | KMT2A (0.50) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8051420 | 0.74 | KMT2A (0.50) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8046746 | 0.73 | KMT2A (0.49) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8041859 | 0.73 | KMT2A (0.49) | KMT2AMAPTMEN1SMN1; SMN2LMNA | |
| SCHEMBL8041857 | 0.73 | KMT2A (0.49) | KMT2AMAPTMEN1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8222203-B2 | Macrocyclic oximyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, HPN, PRSS1 | KMT2A 2340/4885MAPT 4520/4885MEN1 4233/4885 |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, SPINT2, CTSV | KMT2A 2790/4885MAPT 4301/4885MEN1 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.